---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002100"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:48:25.071272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B

## Summary
- Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.
- Preliminary data as company finalizes 2023 financial results; Ernst & Young not audited.
- Update provided at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.
- Additional material information expected in final financial statements; caution against undue reliance.

## SEC filing metadata
- accession: 0001104659-24-002100
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002100
- JSON: https://secwatch.observer/filing/0001104659-24-002100.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002100.txt

## Key facts
- Earnings Releases
  NOVAVAX INC updated its the year ended December 31, 2023 guidance (reaffirmed).
  - Period: the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: On January 8, 2024, Novavax, Inc. (the “Company”) provided an update for investors in which it reaffirmed its guidance for full year 2023 combined research and development and selling, general and administrative expenses, which is anticipated to be between $1.15 billion and $1.25 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.